by Lyla El-Fayomi | Mar 26, 2025
Some big trends to discuss this month, as well as one-off headlines. I have clinical updates on epilepsy, tooth regeneration and Parkinson’s – a disease area quickly becoming an RMNU🔬 staple, given all the movement in this field! Read on, bookmark for later, or send...
by Cal Strode | Mar 11, 2025
“Every administration has its headwinds and tailwinds” said Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM), when examining the impact of the two most recent U.S. administrations at ARM’s 2025 State of the Industry Briefing in January. Credit: Alliance for...
by Laya Kiani | Mar 6, 2025
The biotechnology sector has always been a hub of innovation, consistently pushing the boundaries of scientific and technological advancements. However, transforming novel discoveries into viable market-ready solutions requires substantial financial backing. Among the...
by Krystal Jacques | Feb 19, 2025
There are many ways the regenerative potential of cell transplantation therapy can be optimized to pave the route to the clinic. They include, but are not limited to, deciding which cells to transplant and looking at whether we should use fresh cells or cryopreserved...
by Stacey Johnson | Jan 31, 2025
In a new location, with highways replacing waterways, it’s comforting to have an agenda with some consistent touchpoints for familiarity, and Advanced Therapies Week 2025 (ATW25), January 20-23 in Dallas, Texas, began with two of my favourites: the Super plenary,...
by Cal Strode | Jan 20, 2025
2025 marks the third time I’ve covered the Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. In 2024’s installation, I noted the strong emphasis on the cell and gene therapy (CGT) industry’s acceleration, driven by scientific...
Comments